Semaglutide (Ozempic) reduces HbA1c by an average of 1.5% and cuts major cardiovascular events by 26% in Phase 3 trials. This guide covers the diabetes-specific research protocol and clinical data.
Semaglutide activates GLP-1 receptors on pancreatic beta cells, stimulating insulin secretion in a glucose-dependent manner — meaning insulin is only released when blood glucose is elevated, significantly reducing hypoglycemia risk compared to sulfonylureas. Semaglutide also suppresses glucagon secretion from alpha cells, reducing hepatic glucose production. Delayed gastric emptying reduces post-meal glucose spikes. GLP-1 receptor activation in the brain reduces appetite and caloric intake, producing the secondary weight loss benefit observed in diabetes trials.
| Compound | Mechanism | HbA1c | Weight | CV Data |
|---|---|---|---|---|
| Semaglutide (Ozempic) | GLP-1 agonist | −1.5% | −4.5 kg | Yes (SUSTAIN-6) |
| Tirzepatide (Mounjaro) | Dual GLP-1/GIP | −2.0% | −8.5 kg | Yes (SURPASS-CVOT) |
| Liraglutide (Victoza) | GLP-1 agonist | −1.2% | −3.0 kg | Yes (LEADER) |
| Metformin | AMPK activation | −1.0% | Neutral | Limited |
Yes. Semaglutide (Ozempic) is FDA-approved for type 2 diabetes management. SUSTAIN-6 and related trials show average HbA1c reductions of 1.5% and significant cardiovascular risk reduction. It works by stimulating insulin secretion in a glucose-dependent manner and suppressing glucagon.
The FDA-approved Ozempic dosing for type 2 diabetes starts at 0.25 mg/week for 4 weeks, then 0.5 mg/week. The dose can be increased to 1 mg/week after 4 weeks if additional glycemic control is needed, and up to 2 mg/week. Research protocols vary from this clinical dosing.
Semaglutide produces greater HbA1c reduction than metformin (−1.5% vs −1.0%) and adds cardiovascular protection and weight loss benefits that metformin does not provide. However, metformin is typically first-line therapy due to its long safety record and low cost. Semaglutide is often added as second-line therapy.
Semaglutide begins lowering fasting blood glucose within 1–2 weeks. Maximum HbA1c reduction is typically achieved by weeks 20–30. The glucose-lowering effect is glucose-dependent — it only stimulates insulin when blood sugar is elevated, reducing hypoglycemia risk.
Semaglutide alone has a low risk of hypoglycemia because its insulin-stimulating effect is glucose-dependent. The risk increases when combined with sulfonylureas or insulin. This is a key advantage over older diabetes medications.
Ozempic (0.5–2 mg/week) is approved for type 2 diabetes. Wegovy (2.4 mg/week) is approved for obesity. Both contain semaglutide. Ozempic is used at lower doses for glycemic control; Wegovy uses a higher dose optimized for maximum weight loss.
Purgo Labs provides pharmaceutical-grade semaglutide with third-party COAs. Use code HEALTH for 15% off.
Buy Semaglutide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.